Opinion|Videos|July 17, 2024
Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses treatment in early relapse of multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.
Advertisement
Related to this article
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
J&J Oncology Care Index Finds Community Innovation Adoption Gap
5